Randomized Safety, Tolerability and Pilot Efficacy of AN-1792 in Alzheimer's Disease

Stopped early · Phase 2

Conditions studied: Alzheimer's Disease

In brief

A multi-center, double-blind, placebo-controlled out-patient, safety, tolerability, and pilot efficacy study of intramuscular AN-1792 in patients with mild to moderate Alzheimer's disease.

Key facts

Study ID

NCT00021723

Run by

JANSSEN Alzheimer Immunotherapy Research & Development, LLC

People needed

375

Starts

2001-09-01

Expected to finish

2003-09-01

Last updated by the study team

2009-09-24

Who can join

Age: 50 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Pivotal Research Centers — Peoria, Arizona, United States
• 21st Century Neurology — Phoenix, Arizona, United States
• California Clinical Trials — Beverly Hills, California, United States
• UCSD Medical Center — La Jolla, California, United States
• Pharmacology Research Institute — Northridge, California, United States
• Baumel-Eisner Neuromedical Institute — Bay Harbor Islands, Florida, United States
• Baumel-Eisner Neuromedical Institute — Boca Raton, Florida, United States
• Baumel-Eisner Neuromedical Institute — Fort Lauderdale, Florida, United States
• Mayo Clinic — Rochester, Minnesota, United States
• Clinical Pharmaceutical Trials, Inc. — Tulsa, Oklahoma, United States
• Baylor College of Medicine — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.